Clinical Trial Update: 89Zr-DFO-girentuximab Expanded Access Program (EAP)

View source ↗

Summary

This clinical trial update indicates that the 89Zr-DFO-girentuximab Expanded Access Program for Clear Cell Renal Cell Carcinoma is available to eligible patient…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• 89Zr-DFO-girentuximab

Snippet

Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited | Conditions: Clear Cell Renal Cell Carcinoma | Status: AVAILABLE